Engineers ene-reductases to improve yields of Sacubitril intermediates, suggesting enhanced synthesis strategies for complex compounds.
The availability of an effective ene-reductase (ER) for the synthesis of Sacubitril intermediates represents a major challenge. Herein, we report the engineering of ClER and GoER utilizing three different substrates to synthesize the key Sacubitril precursor. The best performing variant, ClER M3 (M35C/Y76C/Q244G/V289P), enables substrate loadings of up to 100 mM with up to 99% yields and ee. This chemoenzymatic strategy provides a valuable platform for the reduction of challenging α,β-unsaturated carboxylic acids bearing large substituents, such as biphenyls or naphthyl motifs.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: